Clinical trials
Phase 2/3 Renal Insufficiency trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2013 | 1 |
| 2016 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Terminated | 4 |
| Unknown status | 4 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayside Health | 1 |
| Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies | 1 |
| Ebima Clifford Okundaye | 1 |
| Helsinki University Central Hospital | 1 |
| Imam Khomeini Hospital | 1 |
| Maquet Cardiovascular | 1 |
| Mario Negri Institute for Pharmacological Research | 1 |
| Matthew Cooper | 1 |
| OPKO Health, Inc. | 1 |
| Ottawa Hospital Research Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency | 18 |
| Kidney Failure, Chronic | 4 |
| Heart Failure | 3 |
| Acute Kidney Injury | 2 |
| Kidney Diseases | 2 |
| Renal Insufficiency, Chronic | 2 |
| Anemia | 1 |
| Arrhythmias, Cardiac | 1 |
| Arteriovenous Fistula | 1 |
| Critical Illness | 1 |
Trials
Showing 76 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.